North Star Investment Management’s ImmunityBio IBRX Stock Holding History

North Star Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10	Closed	-$51	–	1319
2022 Q4	$51	Hold	10	–	–	﹤0.01%	1304
2022 Q3	$0	Hold	10	–	–	﹤0.01%	1153
2022 Q2	$0	Hold	10	–	–	﹤0.01%	1153
2022 Q1	$0	Hold	10	–	–	﹤0.01%	1170
2021 Q4	$0	Sell	10 -990	-99%	-$7.44K	﹤0.01%	1197
2021 Q3	$10K	Buy	1,000 +990	+9,900%	+$10.9K	﹤0.01%	868
2021 Q2	$0	Buy	+10	New	+$165	﹤0.01%	1104
2021 Q1	–	Sell	-5,000	Closed	-$67K	–	1070
2020 Q4	$67K	Hold	5,000	–	–	0.01%	494
2020 Q3	$35K	Hold	5,000	–	–	﹤0.01%	570
2020 Q2	$61K	Buy	+5,000	New	+$28.2K	0.01%	464

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

North Star Investment Management's IBRX Position: Q1 2023 in Review

North Star Investment Management sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 10 shares — an estimated $51 sold.

North Star Investment Management first reported a position in IBRX in Q2 2020 and held it in 10 quarters. The position peaked at $67K in Q4 2020. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

North Star Investment Management reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
North Star Investment Management sold 10 ImmunityBio shares in Q1 2023, an estimated $51.
North Star Investment Management first reported a position in ImmunityBio in Q2 2020 and held it in 10 quarters.
North Star Investment Management's ImmunityBio position peaked at $67K in Q4 2020.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on North Star Investment Management's 13F filing for Q1 2023, filed 27 Apr 2023.